Abstract:Abstract Huntington’s disease is caused by a CAG / polyglutamine repeat expansion. Mutated CAG repeats undergo somatic instability, resulting in tracts of several hundred CAGs in the brain; and genetic modifiers of Huntington’s disease have indicated that somatic instability is a major driver of age of onset and disease progression. As the CAG repeat expands, the likelihood that exon 1 does not splice to exon 2 increases, resulting in two transcripts that encode full-length huntingtin protein, as well as the highly pathogenic and aggregation-prone exon 1 huntingtin protein. Strategies that target the huntingtin gene or transcripts are a major focus of therapeutic development. It is essential that the levels of all isoforms of huntingtin protein can be tracked, to better understand the molecular pathogenesis, and to assess the impact of huntingtin protein-lowering approaches in preclinical studies and clinical trials. Huntingtin protein bioassays for soluble and aggregated forms of huntingtin protein are in widespread use on the homogeneous time-resolved fluorescence and Meso Scale Discovery platforms, but these do not distinguish between exon 1 huntingtin protein and full-length huntingtin protein. In addition, they are frequently used to quantify huntingtin protein levels in the context of highly expanded polyglutamine tracts, for which appropriate protein standards do not currently exist. Here, we set out to develop novel huntingtin protein bioassays to ensure that all soluble huntingtin protein isoforms could be distinguished. We utilized the zQ175 Huntington’s disease mouse model that has ∼190 CAGs, a CAG repeat size for which protein standards are not available. Initially, 30 combinations of six antibodies were tested on three technology platforms: homogeneous time-resolved fluorescence, amplified luminescent proximity homogeneous assay and Meso Scale Discovery, and a triage strategy was employed to select the best assays. We found that, without a polyglutamine-length-matched standard, the vast majority of soluble mutant huntingtin protein assays cannot be used for quantitative purposes, as the highly expanded polyglutamine tract decreased assay performance. The combination of our novel assays, with those already in existence, provides a tool-kit to track: total soluble mutant huntingtin protein, soluble exon 1 huntingtin protein, soluble mutant huntingtin protein (excluding the exon 1 huntingtin protein) and total soluble full-length huntingtin protein (mutant and wild type). Several novel aggregation assays were also developed that track with disease progression. These selected assays can be used to compare the levels of huntingtin protein isoforms in a wide variety of mouse models of Huntington’s disease and to determine how these change in response to genetic or therapeutic manipulations.

Detection of HTTex1p by western blot and immunostaining of HD human and mouse brain using neo-epitope antibody P90 highlights impact of CAG repeat expansion on its size, solubility, and response to MSH3 silencing

Mutant HTT protein decreases with CAG repeat expansion: implications for therapeutics and bioassays.

Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification

Native Mutant Huntingtin in Human Brain

Cell-type-specific CAG repeat expansions and toxicity of mutant Huntingtin in human striatum and cerebellum

Expression of the Huntington's Disease (IT15) Protein Product in HD Patients.

Msh3 and Pms1 Set Neuronal CAG-repeat Migration Rate to Drive Selective Striatal and Cortical Pathogenesis in HD Mice

Integrative determination of the atomic structure of mutant huntingtin exon 1 fibrils implicated in Huntington’s disease

Systematic Uncovering of Multiple Pathways Underlying the Pathology of Huntington Disease by an Acid-Cleavable Isotope-Coded Affinity Tag Approach

Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platforms

Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction

Microglial proliferation and astrocytic protein alterations in the human Huntington's disease cortex

Pathological Polyq Expansion Does Not Alter the Conformation of the Huntingtin-HAP40 Complex.

Interaction between Huntingtin exon 1 and HEAT repeat structure probed by chimeric model proteins

Expression of the Mutant Allele of IT-15 (the HD Gene) in Striatum and Cortex of Huntington's Disease Patients.

Widespread expression of Huntington's disease gene (IT15) protein product

Cell-intrinsic glial pathology is conserved across human and murine models of Huntington's disease

Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice

A Huntingtin-Associated Protein Enriched in Brain with Implications for Pathology

Lack of Association of Somatic CAG Repeat Expansion with Striatal Neurodegeneration in HD Knock-in Animal Models

Patterns of CAG repeat instability in the central nervous system and periphery in Huntington’s disease and in spinocerebellar ataxia type 1